GS-3242

DRUG3 trials

Sponsors

Gilead Sciences Inc., Gilead Sciences

Conditions

HIV-1 InfectionHIV-1-infectionhuman immunodeficiency virus type 1 (HIV-1)

Phase 1

Study of GS-3242 in Participants With HIV-1; Substudy-05

CompletedNCT07001319

Gilead SciencesHIV-1-infection

Start: 2025-05-29End: 2026-04-16Updated: 2026-05-11

Phase 2

Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels

RecruitingNCT07841990

Gilead SciencesHIV-1 Infection

Start: 2026-10-01End: 2033-07-01Target: 125Updated: 2026-10-23

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

Not yet recruitingCTIS2026-526026-40-00

Gilead Sciences Inc.human immunodeficiency virus type 1 (HIV-1)

Target: 38Updated: 2026-10-09